肺肉瘤样癌是一种罕见的非小细胞肺癌(NSCLC)亚型,预后不良。在太平洋III期研究中,与安慰剂相比,durvalumab显著改善了无进展生存期和总生存期,在同步放化疗后没有疾病进展的III期NSCLC患者中。然而,因疾病进展而停用durvalumab的患者的治疗,是未知的。
我们报告了一例在III期肺肉瘤样癌放化疗后Durvalumab巩固治疗期间,对pembrolizumab的反应良好的患者,该患者具有高程序性细胞死亡配体1(PD-L1)和PD-L2表达。
这里,我们提出了什么,据我们所知,是首例报道的III期肺肉瘤样癌患者行确定性放化疗后durvarumab抵抗被派姆单抗克服的病例.
Pulmonary sarcomatoid carcinoma is a rare non-small-cell lung cancer (NSCLC) subtype with a poor prognosis. In the phase III PACIFIC study, durvalumab significantly improved progression-free survival and overall survival versus placebo, in patients with stage III NSCLC who do not have disease progression after concurrent chemoradiotherapy. However, treatments for patients who discontinue durvalumab due to disease progression, are unknown.
We report a
case of favorable response to pembrolizumab in a patient with disease progression during durvalumab consolidation therapy after chemoradiotherapy for stage III pulmonary sarcomatoid carcinoma with high programmed cell death ligand 1 (PD-L1) and PD-L2 expression.
Here, we present what, to the best of our knowledge, is the first reported
case in which durvarumab resistance after definitive chemoradiotherapy in a patient with stage III pulmonary sarcomatoid carcinoma was overcome by pembrolizumab.